Section Arrow
Quote
BOLT.NASDAQ
- Bolt Biotherapeutics Inc
Quotes are at least 15-min delayed:2026/01/07 07:13 EST
Pre Market
Last
 --
-- (--)
Bid
4.8
Ask
6.24
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 5.88
+0.22 (+3.89%)
Day High 
5.9599 
Prev. Close
5.66 
1-M High
6.15 
Volume 
17.58K 
Bid
4.8
Ask
6.24
Day Low
5.5 
Open
5.5 
1-M Low
5 
Market Cap 
10.86M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.41 
20-SMA 5.47 
50-SMA 5.26 
52-W High 11.7 
52-W Low 4.41 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-22.21/-12.36
Enterprise Value
33.82M
Balance Sheet
Book Value Per Share
16.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
231.00K
Operating Revenue Per Share
3.53
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics1.95+0.57+41.30%-- 
Pre Market 1.91 -0.04 -2.05%
ALMSAlumis Inc.16.23+7.92+95.31%0.33PE
Pre Market 17.1 +0.87 +5.36%
MREOMereo BioPharma Group plc0.379-0.1016-21.14%-- 
Pre Market 0.4052 +0.0262 +6.91%
SLSSELLAS Life Sciences Group4.1-0.9-18.00%-- 
Pre Market 4.05 -0.05 -1.22%
RXRXRecursion Pharmaceuticals4.55+0.18+4.12%-- 
Pre Market 4.54 -0.01 -0.22%
Industry overview quotes are at least 15 minutes delayed
Business Description
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.